Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial

Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial

A quadrivalent high-dose inactivated influenza vaccine (IIV4-HD) is licensed for adults ≥65 y of age based on immunogenicity and efficacy studies. However, IIV4-HD has not been evaluated in adults aged 60–64 y. This study compared immunogenicity and safety of IIV4-HD with a standard-dose quadrivalen...

Full description

Bibliographic Details
Main Authors: Stephanie Pepin, Jean-François Nicolas, Henryk Szymanski, Isabel Leroux-Roels, Thomas Schaum, Marc Bonten, Giancarlo Icardi, Anju Shrestha, Cynthia Tabar, The QHD00011 study team
Format: Article
Language:English
Published: Taylor & Francis Group 2021-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
high-dose influenza vaccine
influenza vaccination
older adults
immunogenicity
safety
phase iii trial
Online Access:http://dx.doi.org/10.1080/21645515.2021.1983387

Internet

http://dx.doi.org/10.1080/21645515.2021.1983387

Similar Items